Emerging & Overhyped

What it measures: Genotyping the APOE gene, which has three common alleles (ε2, ε3, ε4). Carrying one or two copies of ε4 substantially raises lifetime risk of late-onset Alzheimer's disease.

Why it matters: APOE ε4 is the strongest and most replicated common genetic risk factor for late-onset Alzheimer's disease.

Evidence: Mayeux R, Saunders AM, Shea S, et al. "Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease." N Engl J Med 1998;338:506–511 established APOE's diagnostic value alongside clinical assessment in symptomatic patients — combining clinical diagnosis with APOE genotype improved diagnostic accuracy (AUC 0.87) over clinical diagnosis alone (AUC 0.84). That is a different question from predictive screening in an asymptomatic person. Since 2023–2024, APOE testing has become more clinically relevant in a specific new context: it is now recommended before starting anti-amyloid therapies (e.g. lecanemab) for early Alzheimer's disease, because ε4 carriers have both a different treatment-response profile and a higher risk of a specific side effect (ARIA). Outside that specific pre-treatment context, or genetic counselling for a strong family history, there is no preventive intervention proven to change an asymptomatic ε4 carrier's trajectory, and result disclosure carries real, studied psychological and insurance/employment-related considerations.

Mayeux R, et al. N Engl J Med. 1998. PubMed: PMID 9468467

What it measures: Stool-based sequencing (16S rRNA or shotgun metagenomics) to profile bacterial composition, often reported as a "diversity score" or list of "good" and "bad" bacteria.

Why it matters: The gut microbiome genuinely influences metabolism, immune function, and possibly mood via the gut-brain axis — an active and legitimate research field.

Evidence: An international consensus statement on microbiome testing in clinical practice (published in The Lancet Gastroenterology & Hepatology, 2024) concluded that evidence supporting the clinical usefulness of microbiome diagnostics is scarce, that commercial providers offer direct-to-consumer tests without regulatory approval or consensus on their value, and that this risks wasting patient resources. A related 2025 analytical study found major discrepancies between different commercial providers testing the same stool sample — inter-provider variability was on the same scale as the biological variability between different people. No stool microbiome test can currently diagnose depression, anxiety, or neurodevelopmental disorders in clinical practice, and there are no regulatory-approved clinical microbiome diagnostic tests as of this review.

International consensus statement on microbiome testing in clinical practice. Lancet Gastroenterol Hepatol. 2024. PubMed: PMID 39647502

What it measures: DNA methylation patterns at specific genomic sites, combined into an algorithmic estimate of "biological age" — well-known versions include the Horvath clock, GrimAge, PhenoAge, and DunedinPACE, and are the basis of most consumer "biological age" tests.

Why it matters: Methylation changes with age in a fairly predictable pattern, and some clocks (particularly GrimAge and DunedinPACE) correlate with future mortality and morbidity better than chronological age alone in population studies — a genuinely interesting research finding.

Evidence: A 2026 review, "From population science to the clinic? Limits of epigenetic clocks as personal biomarkers," concluded that epigenetic clocks fail to meet common standards for clinical utility compared with established biomarkers, and that applying them to individual-level decision-making can be uninformative and potentially harmful — citing unresolved technical issues (clock construction methods, sample handling, computational implementation) and biological issues (tissue specificity, sensitivity to environmental and sociodemographic context, limited replication across diverse populations). Their conclusion: even if the technical and biological hurdles are eventually overcome, epigenetic clocks as currently understood should not be used to make individual-level decisions.

"From population science to the clinic? Limits of epigenetic clocks as personal biomarkers." PubMed: PMID 41403206

What it is: Pre-packaged bundles combining dozens of the tests above — often mixing genuinely Strong tests (CBC, lipids, HbA1c) with Weak or Emerging ones (epigenetic clock, full-body MRI, microbiome test) into a single "premium" price tag, sometimes S$3,000–15,000+.

Why it's flagged here: Bundling doesn't average out the evidence quality of its components — a package is only as trustworthy as its weakest constituent test, and the marketing framing ("comprehensive," "leave no stone unturned") actively works against the evidence-based principle that more testing in a low-pretest-probability population increases false positives, incidental findings, downstream anxiety, and unnecessary follow-up procedures without a proven mortality or morbidity benefit.

Evidence: There is no published trial evidence that any specific "longevity panel" bundle, as a package, improves mortality or morbidity outcomes compared with guideline-based, risk-stratified testing. A Cochrane systematic review of general health checks in adults (Krogsbøll et al., PMID 30699470, 15 RCTs, 250,000+ participants) found no reduction in all-cause, cardiovascular, or cancer mortality from inviting asymptomatic adults to general health checks. The individual components should be evaluated — and paid for — on their own evidence, not on the appeal of the bundle.